Skip to content
Annika Bansal – Lifestyle
Author:
Immutep Limited
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
October 23, 2026
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
October 14, 2026
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 13, 2026
Immutep Receives ~A$0.86 Million R&D Tax Incentive
September 30, 2026
Change to American Depositary Share Ratio
September 21, 2026
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
September 11, 2026
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
July 24, 2026
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
July 14, 2026
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
July 13, 2026
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
June 4, 2026
1
2
Next Page
→